Sacral Nerve Stimulation Market Size Worth $2.39 Billion By 2026

The global sacral nerve stimulation market size is anticipated to reach USD 2.39 billion by 2026 registering a CAGR of 13.7%, according to a new report by Grand View Research, Inc. Increasing incidence of urge incontinence and fecal incontinence is anticipated to boost the market growth. Several other factors that are expected to drive the market include increase in number of patients suffering from urge incontinence, urgency frequency and urinary retention. According to the Department of Obstetrics and Gynecology, India, urge incontinence affects 23.0 to 55.0% of women.

Increasing number of patients suffering from Urinary Tract Infection (UTI) is also contributing toward the market growth. UTI is very common in females. Technological advancements are also likely to boost market growth. For instance, Medtronic InterStim II neurostimulation system. This system electrically stimulates the sacral nerves to normalize neural communication between the bladder and the brain, and between the bowel and the brain. It is designed for the treatment of urinary retention, Overactive Bladder (OAB) including urinary urge incontinence and symptoms, such as urgency frequency in patients who had failed to tolerate more conservative treatments.

Click the link below:

Further key findings from the study suggest:

  • Implantable devices led the global sacral nerve stimulation (SNS) market in 2018 due to increased number of patients suffering from OAB and urinary incontinence
  • Urine and fecal incontinence application segment is expected to witness the fastest CAGR from 2018 to 2026 owing to increasing cases of urine and fecal incontinence
  • North America led the SNS market in 2018 and will maintain its dominance throughout the forecast years owing to the rising cases of urge incontinence, OAB, and UTI and increasing investments in the development of innovative SNS systems
  • Some of the key companies in the global sacral nerve stimulation market are Medtronic PLC; Axonics Modulation Technologies, Inc.; Nuvectra; and Cogentix Medical

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s